Therapeutic Workshop
Diabetes: "New Mechanisms, New Opportunities"
Monday, February 11, 2008
9:30 AM
Basildon Room
The recent dramatic controversy surrounding Avandia has brought the topic of diabetes treatments (and their safety profiles) back to the top of everyone?s minds. There are plenty of new drug classes in development to treat this important and costly disease. Audience members will learn about what lies ahead, beyond Avandia.
Moderators
- Liana Moussatos; Analyst, Pacific Growth Equities
Panelists
- Douglas J. Ringler, V.M.D.; President and CEO, Tolerx
- Alan M. Solinger, M.D., FACP FACR; Vice President, Clinical Immunology, XOMA
- Dr. Solomon Steiner; Chairman, President and CEO, Biodel
- Kenneth Snow, M.D.; Chief, Adult Diabetes Section, The Joslin Clinic
Who's Who
Expert: Kenneth Snow, MD, is Chief, Adult Diabetes Section at the Joslin Clinic, a multi-specialty practice devoted to the treatment of diabetes in Boston, Massachusetts. He is also Director of the Sexual Function Clinic at the Joslin. Dr. Snow has experience in the treatment of diabetes mellitus and is involved in several clinical research projects from Phase I to Phase IV trials. He is Clinical Instructor at Harvard Medical School and is on the National Speakers Bureau for numerous pharmaceutical companies.